Physician profile
James Stewart Reeves
NPI 1699040618
$4,583.94
in general payments reported to CMS, 2019-2025
32 companies · $251 in 2025
The $251 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,118 · 2020: $987 · 2021: $753 · 2022: $345 · 2023: $1,097 · 2024: $32.67 · 2025: $251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,380.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $715.50 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $591.56 | 2019-2025 | Repatha, Otezla |
| Lilly USA, LLC | $569.39 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $476.77 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $463.38 | 2021-2023 | |
| Glaxosmithkline, LLC. | $372.39 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $255.39 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $157.72 | 2019-2020 | |
| Abbott Laboratories | $150.75 | 2022-2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $115.18 | 2019-2021 | |
| Allergan, INC. | $95.31 | 2019-2020 | |
| Amarin Pharma, INC. | $92.13 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.82 | 2020-2023 | Jardiance |
| Corium, LLC | $54.74 | 2023 | Azstarys |
| Esperion Therapeutics, INC. | $38.52 | 2020-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.20 | 2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $34.64 | 2019-2020 | |
| Exact Sciences Corporation | $34.14 | 2025 | The Cologuard Plus Collection Kit |
| Sunovion Pharmaceuticals INC. | $29.05 | 2020 | |
| Dexcom, INC. | $27.81 | 2023-2024 | Dexcom G6 Transmitter |
| Nestle Healthcare Nutrition INC. | $26.77 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $26.09 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $23.90 | 2023 | Rexulti |
| Upsher-Smith Laboratories LLC | $16.58 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.40 | 2022 | |
| Sanofi Pasteur INC. | $14.79 | 2025 | |
| Novartis Pharmaceuticals Corporation | $14.54 | 2019 | |
| Idorsia Pharmaceuticals US INC | $14.11 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.71 | 2021 | |
| Alexion Pharmaceuticals, INC. | $12.60 | 2020 | |
| Janssen Pharmaceuticals, INC | $12.25 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $10.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Reeves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.